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AbstrAct
Objective
To derive and validate a risk prediction algorithm to 
estimate hospital admission and mortality outcomes 
from coronavirus disease 2019 (covid-19) in adults.
Design
Population based cohort study.
setting anD participants
QResearch database, comprising 1205 general 
practices in England with linkage to covid-19 test 
results, Hospital Episode Statistics, and death registry 
data. 6.08 million adults aged 19-100 years were 
included in the derivation dataset and 2.17 million 
in the validation dataset. The derivation and first 
validation cohort period was 24 January 2020 to 30 
April 2020. The second temporal validation cohort 
covered the period 1 May 2020 to 30 June 2020.
Main OutcOMe Measures
The primary outcome was time to death from covid-19, 
defined as death due to confirmed or suspected 
covid-19 as per the death certification or death 
occurring in a person with confirmed severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection in the period 24 January to 30 April 2020. The 
secondary outcome was time to hospital admission 
with confirmed SARS-CoV-2 infection. Models were 
fitted in the derivation cohort to derive risk equations 
using a range of predictor variables. Performance, 
including measures of discrimination and calibration, 
was evaluated in each validation time period.
results
4384 deaths from covid-19 occurred in the derivation 
cohort during follow-up and 1722 in the first 
validation cohort period and 621 in the second 
validation cohort period. The final risk algorithms 
included age, ethnicity, deprivation, body mass index, 
and a range of comorbidities. The algorithm had good 
calibration in the first validation cohort. For deaths 
from covid-19 in men, it explained 73.1% (95% 
confidence interval 71.9% to 74.3%) of the variation 
in time to death (R2); the D statistic was 3.37 (95% 
confidence interval 3.27 to 3.47), and Harrell’s C was 
0.928 (0.919 to 0.938). Similar results were obtained 
for women, for both outcomes, and in both time 
periods. In the top 5% of patients with the highest 
predicted risks of death, the sensitivity for identifying 
deaths within 97 days was 75.7%. People in the top 
20% of predicted risk of death accounted for 94% of 
all deaths from covid-19.
cOnclusiOn
The QCOVID population based risk algorithm 
performed well, showing very high levels of 
discrimination for deaths and hospital admissions 
due to covid-19. The absolute risks presented, 
however, will change over time in line with the 
prevailing SARS-C0V-2 infection rate and the extent 
of social distancing measures in place, so they 
should be interpreted with caution. The model can be 
recalibrated for different time periods, however, and 
has the potential to be dynamically updated as the 
pandemic evolves.
Introduction
The first cases of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) infection were reported in 
the UK on 24 January 2020, with the first death from 
coronavirus disease 2019 (covid-19) on 28 February 
2020. As of 18 August 2020, more than 41 000 deaths 
from covid-19 had occurred in the UK and more than 
773 000 deaths globally.1 In the initial absence of any 
vaccination or prophylactic or curative treatments, the 
UK government implemented social distancing and 
shielding measures to suppress the rate of infection 
and protect vulnerable people, thereby trying to 
minimise the risk of serious adverse outcomes.2 3
Emerging evidence throughout the course of the 
pandemic, initially from case series and then from 
cohorts of patients with confirmed SARS-CoV-2 
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WhAt Is AlreAdy knoWn on thIs topIc
Public policy measures and clinical risk assessment relevant to covid-19 can be 
aided by rigorously developed and validated risk prediction models
Published risk prediction models for covid-19 are subject to a high risk of bias 
with optimistic reported performance, raising concern that these models may be 
unreliable when applied in practice
WhAt thIs study Adds
Novel clinical risk prediction models (QCOVID) have been developed and 
evaluated to identify risks of short term severe outcomes due to covid-19
The risk models have excellent discrimination and are well calibrated; they will 
be regularly updated as the absolute risks change over time
QCOVID has the potential to support public health policy by enabling shared 
decision making between clinicians and patients, targeted recruitment for 
clinical trials, and prioritisation for vaccination
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infection, has shown associations of age, sex, certain 
comorbidities, ethnicity, and obesity with adverse 
covid-19 outcomes such as hospital admission or 
death.4-11 The knowledge base regarding risk factors 
for severe covid-19 is growing. As many countries are 
cautiously attempting to ease “lockdown” measures or 
reintroduce measures if rates are rising, an opportunity 
exists to develop more nuanced guidance based on 
predictive algorithms to inform risk management 
decisions.12 Better knowledge of individuals’ risks 
could also help to guide decisions on mitigating 
occupational exposure and in targeting of vaccines to 
those most at risk. Although some prediction models 
have been developed, a recent systematic review found 
that they all have a high risk of bias and that their 
reported performance is optimistic.13
The use of primary care datasets with linkage to 
registries such as death records, hospital admissions 
data, and covid-19 testing results represents a novel 
approach to clinical risk prediction modelling for 
covid-19. It provides accurately coded, individual level 
data for very large numbers of people representative of 
the national population. This approach draws on the 
rich phenotyping of individuals with demographic, 
medical, and pharmacological predictors to allow 
robust statistical modelling and evaluation. Such 
linked datasets have an established track record for the 
development and evaluation of established clinical risk 
models, including those for cardiovascular disease, 
diabetes, and mortality.14-16 We aimed to develop 
and validate population based prediction models 
to estimate the risks of becoming infected with and 
subsequently dying from covid-19 and of becoming 
infected and subsequently admitted to hospital with 
covid-19. The model we have developed is designed 
to be applied across the adult population so that it 
can be used to enable risk stratification for public 
health purposes in the event of a “second wave” of 
the pandemic, to support shared management of risk 
and occupational exposure, and in early targeting of 
vaccines to people most at risk. An ongoing companion 
study will externally validate the models, using 
datasets across all four nations of the UK, and will be 
reported separately.
Methods
This study was commissioned by the Chief Medical 
Officer for England on behalf of the UK Government, 
who asked the New and Emerging Respiratory Virus 
Threats Advisory Group (NERVTAG) to establish 
whether a clinical risk prediction model for covid-19 
could be developed in line with the emerging evidence. 
The protocol has been published.17 The study was 
conducted in adherence with TRIPOD18 and RECORD19 
guidelines and with input from our patient advisory 
group.
study design and data sources
We did a cohort study of primary care patients using 
the QResearch database (version 44). QResearch was 
established in 2002 and has been extensively used 
for the development of risk prediction algorithms 
across the National Health Service (NHS) and for 
epidemiological research. By April 2020, 1205 
practices in England were contributing to QResearch, 
covering a population of 10.5 million patients. The 
database is linked at individual patient level, using 
a project specific pseudonymised NHS number, to 
hospital admissions data (including intensive care unit 
data), positive results from covid-19 real time reverse 
transcriptase polymerase chain reaction tests held by 
Public Health England, cancer registrations (including 
detailed radiotherapy and systemic chemotherapy 
records), the national covid-19 shielded patient list in 
England, and mortality records held by NHS Digital.
We identified a cohort of people aged 19-100 years 
registered with participating general practices in 
England on 24 January 2020. We excluded patients 
(approximately 0.1%) who did not have a valid NHS 
number. Patients entered the cohort on 24 January 
2020 (date of first confirmed case of covid-19 in the 
UK) and were followed up until they had the outcome 
of interest or the end of the first study period (30 April 
2020), which was the date up to which linked data 
were available at the time of the derivation of the 
model, or the second time period (1 May 2020 until 30 
June 2020) for the temporal cohort validation.
Outcomes
The primary outcome was time to death from covid-19 
(either in hospital or outside hospital), defined as 
confirmed or suspected death from covid-19 as per the 
death certification or death occurring in an individual 
with confirmed SARS-CoV-2 infection at any time in 
the period 24 January to 30 April 2020. The secondary 
outcome was time to hospital admission with covid-19, 
defined as an ICD-10 (International Classification of 
Diseases, 10th revision) code for either confirmed 
or suspected covid-19 or new hospital admission 
associated with a confirmed SARS-CoV-2 infection in 
the study period.
predictor variables
We selected candidate predictor variables on the basis 
of the presence of existing clinical vulnerability group 
criteria (table 1), associations with outcomes in other 
respiratory diseases, or hypothesised to be linked to 
adverse outcomes on clinical/biological plausibility 
and likely to be available for implementation. They are 
summarised in box 1 and supplementary box A. We 
defined variables according to information recorded 
using Read Codes in general practices’ electronic 
health records at the start of the study period. The 
exception to this was information on chemotherapy, 
radiotherapy, and transplants, which was based on 
linked hospital records.
QcOviD model development
We randomly allocated 75% of practices to the 
derivation dataset, which we used to develop the 
models. We evaluated the models’ performance in 
the remaining 25% of practices (the validation set). 
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All models were fitted separately in men and women. 
The outcomes of interest are subject to competing 
risks. For the primary outcome of death from covid-19, 
the competing risk is death due to other causes. 
For the secondary outcome of hospital admission, 
the competing risk is death from any cause before 
admission. We fitted a sub-distribution hazard (Fine 
and Gray21) model for each outcome to account for 
competing risks. Individuals who did not have the 
outcome of interest were censored at the study end 
date, including those who had a competing event.
For all predictor variables, we used the most recently 
available value at the entry date (24 January 2020). We 
used second degree fractional polynomials to model 
non-linear relations for continuous variables (age, body 
mass index, and Townsend material deprivation score, 
an area level score based on postcode20). Initially, we 
fitted a complete case analysis by using a model within 
the derivation data to derive the fractional polynomial 
terms. For indicators of comorbidities and medication 
use, we assumed the absence of recorded information 
to mean absence of the factor in question. Data 
were missing in four variables: ethnicity, Townsend 
score, body mass index, and smoking status. We 
used multiple imputation with chained equations 
under the missing at random assumption to replace 
missing values for these variables. For computational 
efficiency, we used a combined imputation model for 
both outcomes. The imputation model was fitted in the 
derivation data and included predictor variables, the 
Nelson-Aalen estimators of the baseline cumulative 
sub-distribution hazard, and the outcome indicators 
(death from covid-19 and hospital admission with 
covid-19). We carried out five imputations. Each 
analysis model was fitted in each of the five imputed 
datasets. We used Rubin’s rules to combine the model 
parameter estimates and the baseline cumulative 
incidence estimates across the imputed datasets.
We initially sought to fit models using all predictor 
variables. Owing to sparse cells, some conditions were 
combined if clinically similar in nature (such as rare 
neurological disorders). We examined interactions 
between body mass index and ethnicity and interactions 
between predictor variables and age, focusing on 
predictor variables that apply across the age range 
(asthma, epilepsy, diabetes, severe mental illness). 
We explored the use of penalised models (LASSO) to 
screen variables for inclusion, but this retained all 
the predictor variables and most interaction terms.17 
In line with the protocol, we subsequently removed a 
small number of variables with low numbers of events 
and adjusted (sub-distribution) hazard ratios close 
to 1 (as these will have minimal effect on predicted 
risks) or with uncertain clinical credibility, defined 
as counterintuitive results in light of the emerging 
literature. Lastly, we combined regression coefficients 
from the final models with estimates of the baseline 
cumulative incidence function evaluated at 97 days to 
derive risk equations for each outcome. We used all the 
available data in the database.
Model evaluation
We did all model evaluation using the validation 
data with two separate periods of follow-up. The 
first validation study period was the same as for the 
derivation cohort: 24 January to 30 April 2020. The 
second temporal validation covered the subsequent 
period of 1 May 2020 to 30 June 2020. This was carried 
out with the same validation cohort except for exclusion 
of patients who died during 24 January to 30 April 
2020. In the validation cohort, we fitted an imputation 
model to replace missing values for ethnicity, body 
mass index, Townsend score, and smoking status. This 
excluded the outcome indicators and Nelson-Aalen 
terms, as the aim was to use covariate data to obtain a 
prediction as if the outcome had not been observed to 
reflect intended use.
We applied the final risk equations developed 
from the derivation dataset to men and women in 
the validation dataset and evaluated R2 values, Brier 
scores, and measures of discrimination and calibration 
for the two time periods.22-24 R2 values refer to the 
proportion of variation in survival time explained by 
the model. Brier scores measure predictive accuracy, 
table 1 | Original population level risk stratification method as exercised in uK*
clinical risk level advice criteria identification and inclusion
Clinically extremely  
vulnerable (high risk)
Shielding (stay at home and  
stringently avoid any  
personal/face-to-face contact)
High risk conditions as established by clinical  
expert group decisions based on available  
evidence at time. Dynamic group of  
approximately 2.2 million people in England
Method 1: core group of patients identified by NHS 
Digital and contacted centrally by NHS England
Method 2: additional patients in particular medical 
sub-specialties not identifiable centrally
Method 3: additional patients identified by secondary 
care specialists using clinical judgment
Method 4: additional patients identified in  
primary care using clinical judgment
Clinically vulnerable  
(medium risk)
Follow stringent social distancing 
measures
Vulnerable group of approximately 16 million 
people in England, based on eligibility for  
influenza vaccination due to age ≥70, pregnancy, 
or comorbidity
NA
Remainder of population 
(low risk)
Follow mandatory social distancing 
measures and “lockdown” measures, 
but no specific clinical advice
NA NA
NA=not applicable.
*Shielding and stringent social distancing are both interventions designed to reduce risk of exposure to SARS-CoV-2, but classification of risk relates to risk of complicated or fatal disease if 
infected and not risk of becoming infected.
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box 1: candidate predictor variables examined during model development*
Demographic
•	Age in years (continuous)
•	Townsend deprivation score (continuous)—This is an area level continuous score based on the patient’s postcode.20 Originally developed by 
Townsend,20 it includes unemployment (as a percentage of those aged ≥16 who are economically active), non-car ownership (as a percentage 
of all households), non-home ownership (as a percentage of all households), and household overcrowding. These variables are measured for a 
given area of approximately 120 households, via the 2011 census, and combined to give a Townsend score for that area. A greater Townsend score 
implies a greater level of deprivation
•	Ethnicity in nine categories (White, Indian, Pakistani, Bangladeshi, Other Asian, Caribbean, Black African, Chinese, other ethnic group)
•	Domicile in three categories: homeless, care home residence (nursing or residential), other
lifestyle
•	Smoking status in five categories (non-smoker, ex-smoker, 1-10 per day, 11-19 per day, ≥20 per day)
•	Body mass index in kg/m2 (continuous)
•	Crack cocaine and injected drug use
conditions on current shielding patient list
•	Solid organ transplant recipient on long term immune suppression treatment
•	Cancers:
 ○Active chemotherapy
 ○Radical radiotherapy for lung cancer
 ○Blood/bone marrow cancer at any treatment stage
 ○ Immunotherapy or continuing antibody treatment
 ○Targeted cancer treatments that affect immune system (PARP inhibitor or PKI)
 ○Bone marrow or stem cell transplant in previous 6 months or remain on immunosuppression
•	Immunosuppression sufficiently increasing infection risk
•	Severe respiratory disease:
 ○Severe asthma (≥3 prescribed courses of steroids in preceding 12 months)
 ○Severe COPD (≥3 prescribed courses of steroids in preceding 12 months)
 ○Cystic fibrosis, interstitial lung disease, sarcoidosis, non-cystic fibrosis bronchiectasis, or pulmonary hypertension
•	Rare diseases or inborn errors of metabolism:
 ○Severe combined immunodeficiency
 ○Homozygous sickle cell disease
•	Pregnant with significant heart disease:
 ○Acquired or congenital
conditions moderately associated with increased risk of complications as per current nHs guidance
•	Chronic, non-severe respiratory disease:
 ○Asthma
 ○COPD (emphysema and chronic bronchitis)
 ○Extrinsic allergic alveolitis
•	Chronic kidney disease (CKD):
 ○CKD stage 3 or 4
 ○End stage renal failure requiring dialysis
 ○End stage renal failure ever undergoing a transplant
•	Cardiac disease:
 ○Congestive cardiac failure
 ○Valvular heart disease
•	Chronic liver disease:
 ○Chronic infective hepatitis (hepatitis B or C)
 ○Alcohol related liver disease
 ○Primary biliary cirrhosis
 ○Primary sclerosing cholangitis
 ○Haemochromatosis
•	Chronic neurological conditions:
 ○Epilepsy
 ○Parkinson’s disease
 ○Motor neurone disease
 ○Cerebral palsy
 ○Dementia (Alzheimer’s, vascular, frontotemporal)
 ○Down’s syndrome
•	Diabetes mellitus:
 ○Type 1
 ○Type 2
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where lower values indicate better accuracy.25 D 
statistics (a discrimination measure that quantifies the 
separation in survival between patients with different 
levels of predicted risks) and Harrell’s C statistics 
(a discrimination metric that quantifies the extent 
to which people with higher risk scores have earlier 
events) were evaluated at 97 days (the maximum follow-
up period available at the time of the derivation of the 
model) and 60 days for the second temporal validation, 
with corresponding 95% confidence intervals.26 
We assessed model calibration by comparing mean 
predicted risks with observed risks by twentieths 
of predicted risk for each of the validation cohorts. 
Observed risks were derived in each of the 20 groups 
by using non-parametric estimates of the cumulative 
incidences. Additionally, we did a recalibration for 
the mortality outcome, using the method proposed by 
Booth et al by updating the baseline survivor function 
based on the temporal validation cohort with the 
prognostic index as an offset term.27 We also applied 
the algorithms to the validation cohort for the first 
time period to define the centile thresholds based 
on absolute risk. We also defined centiles of relative 
risk (defined as the ratio of the individual’s predicted 
absolute risk to the predicted absolute risk for a person 
of the same age and sex with a white ethnicity, body 
mass index of 25, and mean deprivation score with no 
other risk factors).
We calculated the performance metrics in the whole 
validation cohort and in the following pre-specified 
•	Conditions or treatments that predispose to infection (eg, steroid treatment):
 ○Rheumatoid arthritis
 ○Systemic lupus erythematosus
 ○Ankylosing spondylitis or other inflammatory arthropathy (eg, psoriatic arthritis)
 ○Connective tissue disease (eg, Ehlers-Danlos syndrome, scleroderma, Sjögren’s syndrome)
 ○Polymyositis or dermatomyositis
 ○Vasculitis (eg, giant cell arteritis, polyarteritis nodosa, Behçet’s syndrome)
Other medical conditions that investigators hypothesised to confer elevated risk 
•	Cardiovascular disease:
 ○Atrial fibrillation
 ○Cardiovascular events (myocardial infarction, stroke, angina, transient ischaemic attack)
 ○Peripheral vascular disease
 ○Treated hypertension
•	Hyperthyroidism
•	Chronic pancreatitis
•	Cirrhosis (if not above; eg, non-alcoholic fatty liver disease)
•	Malabsorption:
 ○Coeliac disease
 ○Steatorrhoea
 ○Blind loop syndrome
•	Peptic ulcer (gastric or duodenal)
•	Learning disability
•	Osteoporosis
•	Fragility fracture (hip, spine, shoulder, or wrist fracture)
•	Severe mental illness:
 ○Bipolar affective disorder
 ○Psychosis
 ○Schizophrenia or schizoaffective disorder
 ○Severe depression
•	HIV infection
•	Hyposplenism
•	Sickle cell disease
•	Sphingolipidoses (eg, Tay-Sachs disease)
•	History of venous thromboembolism
•	Tuberculosis
concurrent medications
•	Drugs affecting the immune response, including systemic chemotherapy based on hospital data
•	Drugs affecting the immune system prescribed in primary care (focus on BNF chapter 8.2)
•	Long acting β agonists
•	Long acting muscarinic antagonists
•	Inhaled corticosteroids
COPD=chronic obstructive pulmonary disease; PARP=poly ADP ribose polymerase; PKI=protein kinase A inhibitor.
*Based on data recorded in general practice record linked to hospital information on chemotherapy, radiotherapy, and transplants
box 1: continued
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subgroups: within age groups (19-39, 40-49, 50-59, 
60-69, 70-79, ≥80 years), within nine ethnic groups, 
and within each of the 10 English regions (where 
numbers allowed). In response to open peer review of 
the published protocol,17 we evaluated performance by 
calculating Harrell’s C statistics in individual general 
practices and combining the results using a random 
effects meta-analysis.28
patient and public involvement
Patients were involved in setting the research question 
and in developing plans for design and implementation 
of the study. Patients were asked to aid in interpreting 
and disseminating the results.
results
Overall study population
Overall, 1205 practices in England met our inclusion 
criteria. Of these, 910 practices were randomly assigned 
to the derivation dataset and 295 to the validation 
cohort. The practices had 8 256 158 registered patients 
aged 19-100 years on 24 January 2020. We included 
6 083 102 of these in the derivation cohort, and the 
validation dataset comprised 2 173 056 people.
baseline characteristics
Table 2 shows the baseline characteristics of patients 
in the derivation cohort. Of these patients, 3 035 409 
(49.9%) were men and 990 799 (16.3%) were of black, 
Asian, or other minority ethnic (BAME) background.
In the derivation cohort, 10 776 (0.18%) patients 
had a covid-19 related hospital admission and 4384 
(0.07%) had a covid-19 related death during the 97 
days’ follow-up, of which 4265 (97.3%) were recorded 
on the death certificate and 119 (2.71%) were based 
only on a positive test (and of these <15 were based 
on a test more than 28 days before death). Admissions 
and deaths due to covid-19 occurred across all regions, 
with the greatest numbers in London, which accounted 
for 3799 (35.3%) of admissions and 1287 (29.4%) 
of deaths. Of those who died, 2517 (57.4%) were 
male, 732 (16.7%) were BAME, 3616 (82.5%) were 
aged 70 and over, 1417 (32.3%) had type 2 diabetes, 
1311 (29.9%) had dementia, and 1033 (23.6%) were 
identified as living in a care home.
The characteristics of the validation cohort were 
similar to those of the derivation cohort, as shown in 
supplementary tables A and B. In the first validation 
period (24 January to 30 April 2020), 1722 deaths and 
3703 hospital admissions due to covid-19 occurred. In 
the second validation period (1 May to 30 June 2020), 
621 deaths and 1002 admissions due to covid-19 
occurred.
predictor variables
The variables included in the final models were 
fractional polynomial terms for age and body mass 
index, Townsend score (linear), ethnic group, domicile 
(residential care, homeless, neither), and a range of 
conditions and treatments as shown in figure 1, figure 2, 
figure 3, and figure 4. These conditions and treatments 
were cardiovascular conditions (atrial fibrillation, heart 
failure, stroke, peripheral vascular disease, coronary 
heart disease, congenital heart disease), diabetes (type 
1 and type 2 and interaction terms for type 2 diabetes 
with age), respiratory conditions (asthma, rare 
respiratory conditions (cystic fibrosis, bronchiectasis, 
or alveolitis), chronic obstructive pulmonary 
disease, pulmonary hypertension or pulmonary 
fibrosis), cancer (blood cancer, chemotherapy, lung 
or oral cancer, marrow transplant, radiotherapy), 
neurological conditions (cerebral palsy, Parkinson’s 
disease, rare neurological conditions (motor neurone 
disease, multiple sclerosis, myasthenia, Huntington’s 
chorea), epilepsy, dementia, learning disability, severe 
mental illness), other conditions (liver cirrhosis, 
osteoporotic fracture, rheumatoid arthritis or systemic 
lupus erythematosus, sickle cell disease, venous 
thromboembolism, solid organ transplant, renal 
failure (CKD3, CKD4, CKD5, with or without dialysis 
or transplant)), and medications (≥4 prescriptions 
from general practitioner in previous six months for 
oral steroids, long acting β agonists or leukotrienes, 
immunosuppressants).
Figure 1 and figure 2 show the adjusted hazard 
ratios in the final models for covid-19 related death in 
the derivation cohort in women and men. Figure 3 and 
figure 4 show the adjusted hazard ratios for the final 
models for covid-19 related hospital admission in the 
derivation cohort.
Supplementary figures A and B show graphs of the 
adjusted hazard ratios for body mass index, age, and 
the interaction between age and type 2 diabetes for 
deaths and hospital admissions due to covid-19 (which 
showed higher risks associated with younger ages). 
Supplementary figures C and D show fully adjusted 
hazard ratios for variables for the full model, including 
variables that were not retained in the final model (for 
example, adjusted hazard ratios close to one or those 
which lacked clinical credibility). Other variables with 
too few events for inclusion were HIV, sphingolipidoises, 
short bowel syndrome, polymyositis, dermatomyositis, 
Ehlers-Danlos syndrome, biliary cirrhosis, hepatitis 
B and C, haemochromatosis, non-alcoholic fatty liver 
disease, chronic pancreatitis, drug misuse, asplenia, 
cholangitis, scleroderma, Sjogren’s syndrome, and 
pregnancy. Supplementary figures E and F show fully 
adjusted hazard ratios for a combined outcome of 
either covid-19 related death or hospital admission. 
This gave very similar absolute risks to the hospital 
admission outcome.
Model evaluation
Discrimination
Table 3 shows the performance of the risk equations 
in the validation cohort for women and men over 97 
days for the main study period and for the temporal 
validation cohort evaluated from 1 May 2020 to 30 
June 2020. Overall, the values for the R2, D, and C 
statistics were similar in women and men. Values for 
the mortality outcome tended to be higher than those 
for the hospital admission outcome. For example, 
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in the first validation period, the equation explained 
74% of the variation in time to death from covid-19 
in women; the D statistic was 3.46, and Harrell’s 
C statistic was 0.933. The corresponding values in 
men were 73.1%, 3.37, and 0.928. The results for 
the second validation period were similar except for 
covid-19 related admissions in women, for which the 
explained variation and discrimination were lower 
than for the first period (explained variation 45.4%, D 
statistic 1.87, and Harrell’s C statistic 0.776).
Supplementary tables C-F show the corresponding 
results by region, age band, and fifth of deprivation 
and within each ethnic group in men and women in 
both validation periods. Performance was generally 
similar to the overall results except for age, for which 
the values were lower within individual age bands.
Figure 5 shows funnel plots of Harrell’s C statistic for 
each general practice in the validation cohort versus 
the number of deaths in each practice in men and 
women in the first validation period. The summary 
(average) C statistic for women was 0.916 (95% 
confidence interval 0.908 to 0.924) from a random 
effects meta-analysis. The corresponding summary C 
statistic for men was 0.919 (0.912 to 0.926).
Calibration
Figure 6 (top two rows) shows the calibration plots 
for the covid-19 related hospital admission equation 
and for the covid-19 related death equation in the 
first validation period. These show that both sets of 
equations were well calibrated in the first time period 
except for a small degree of under-prediction in the 
highest risk category for mortality. In the second 
validation period, calibration was good for the hospital 
admission outcome but not for the mortality outcome 
at the high levels of risk (fig 6, third and fourth rows). 
The calibration was improved with recalibration, with 
observed risks more closely matching the predicted 
risks (fig 6, bottom row).
Risk stratification
Table 4 shows the sensitivity values for the mortality 
equation over 97 days evaluated at different thresholds 
based on the centiles of the predicted absolute risk 
in the validation cohort. For example, it shows that 
75.73% of deaths occurred in people in the top 5% 
for predicted absolute risk of death from covid-19 
(predicted absolute risks above 0.237%). People in the 
top 20% for predicted absolute risk of death accounted 
for 94% of deaths, and the top 25% accounted for 
95.99% of deaths. Supplementary table G shows a 
similar table based on centiles of relative risk. This 
example shows that 50.93% of deaths occurred in 
people in the top 5% for predicted relative risk of 
covid-19 related death (predicted relative risk above 
5.3). People in the top 20% for predicted relative risk 
of death accounted for 77.53% of deaths, and the top 
25% accounted for 81.59% of deaths. As an example, 
table 5 shows characteristics of the 5% of patients 
with the highest predicted absolute risk of death for all 
individuals aged 19-100 years.
Supplementary figures G and H show two clinical 
examples from the web calculator (https://qcovid.
org/BMJ/), showing the absolute and relative risk 
of catching and dying from covid-19 and the risk of 
hospital admission due to covid-19. It also shows a 
ranking of mortality risk based on centiles across the 
validation cohort. Supplementary figure G shows a 
55 year old black African man with type 2 diabetes, 
a body mass index of 27.7, and no other risk factors. 
His absolute risk of catching and dying from covid-19 
over the 90 day period is 0.1095% (or 1 in 913). His 
relative risk compared with a white man aged 55 years 
and a body mass index of 25 is 10.84. The graph 
shows that he is in the top 10% of the population at 
highest risk. Supplementary figure H shows a 30 year 
old white woman with Down’s syndrome with a body 
mass index of 40. Her absolute risk of catching and 
dying from covid-19 is 0.024% (or 1 in 4184). Her 
relative risk compared with a white woman aged 30 
years with a body mass index of 25 and no other risk 
factors is 59.75, and the rank is 75. Her absolute risk 
of admission to hospital with covid-19 over 90 days is 
1 in 272.
discussion
We have developed and evaluated a novel clinical 
risk prediction model (QCOVID) to estimate risks of 
hospital admission and mortality due to covid-19. 
We have used national linked datasets from general 
practice and national SARS-CoV-2 testing, death 
registry, and hospital episode data for a sample 
of more than 8 million adults representative of 
the population of England. The risk models have 
excellent discrimination (Harrell’s C statistics >0.9 
for the primary outcome). Although the calibration 
for the hospital admission outcome was good in both 
time periods, some under-prediction existed for the 
mortality outcome in the second validation cohort, 
which improved after recalibration. The recalibration 
method could be used to transport the risk models to 
other settings or time periods with different absolute 
risks of covid-19. QCOVID represents a new approach 
for risk stratification in the population. It could also 
be deployed in several health and care applications, 
either during the current phase of the pandemic or in 
subsequent “waves” of infection (with recalibration 
as needed). These could include supporting targeted 
recruitment for clinical trials, prioritisation for 
vaccination, and discussions between patients and 
clinicians on workplace or health risk mitigation—for 
example, through weight reduction as obesity may 
be an important modifiable risk factor for serious 
complications of covid-19 if a causal association is 
established.10 Although QCOVID has been specifically 
designed to inform UK health policy and interventions 
to manage covid-19 related risks, it also has 
international potential, subject to local validation. One 
of the variables in our model (the Townsend measure 
of deprivation) may need to be replaced with locally 
available equivalent measures, or some recalibration 
may be needed. Previous risk prediction models based 
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characteristic
Derivation cohort—total 
(n=6 083 102)
Derivation cohort—covid-19 
deaths (n=4384)
Derivation cohort—covid-19 
admission (n=10 776)
Male sex 3 035 409 (49.90) 2517 (57.41) 5962 (55.33)
Mean (SD) age, years 48.21 (18.57) 80.27 (12.10) 69.63 (17.91)
Age band:
 19-29 years 1 139 120 (18.73) 12 (0.27) 282 (2.62)
 30-39 years 1 190 905 (19.58) 22 (0.50) 523 (4.85)
 40-49 years 1 021 643 (16.79) 51 (1.16) 828 (7.68)
 50-59 years 1 013 599 (16.66) 223 (5.09) 1371 (12.72)
 60-69 years 757 483 (12.45) 460 (10.49) 1677 (15.56)
 70-79 years 586 164 (9.64) 892 (20.35) 2135 (19.81)
 80-89 years 298 093 (4.90) 1722 (39.28) 2722 (25.26)
 ≥90 years 76 095 (1.25) 1002 (22.86) 1238 (11.49)
Geographical region:
 East Midlands 164 502 (2.70) 52 (1.19) 131 (1.22)
 East of England 186 673 (3.07) 136 (3.10) 317 (2.94)
 London 1 576 616 (25.92) 1287 (29.36) 3799 (35.25)
 North East 163 388 (2.69) 87 (1.98) 243 (2.26)
 North West 1 076 590 (17.70) 942 (21.49) 2055 (19.07)
 South Central 824 558 (13.55) 563 (12.84) 1293 (12.00)
 South East 685 960 (11.28) 462 (10.54) 960 (8.91)
 South West 581 014 (9.55) 198 (4.52) 501 (4.65)
 West Midlands 605 752 (9.96) 533 (12.16) 1197 (11.11)
 Yorkshire and Humber 218 049 (3.58) 124 (2.83) 280 (2.60)
Ethnicity:
 White 3 924 110 (64.51) 2947 (67.22) 6790 (63.01)
 Indian 175 909 (2.89) 131 (2.99) 423 (3.93)
 Pakistani 114 727 (1.89) 69 (1.57) 248 (2.30)
 Bangladeshi 87 491 (1.44) 69 (1.57) 173 (1.61)
 Other Asian 110 579 (1.82) 57 (1.30) 248 (2.30)
 Caribbean 69 166 (1.14) 152 (3.47) 392 (3.64)
 Black African 150 022 (2.47) 122 (2.78) 456 (4.23)
 Chinese 58 511 (0.96) 18 (0.41) 45 (0.42)
 Other ethnic group 224 394 (3.69) 114 (2.60) 436 (4.05)
 Not recorded 1 168 193 (19.20) 705 (16.08) 1565 (14.52)
Townsend deprivation fifth:
 1 (most affluent) 1 238 575 (20.36) 840 (19.16) 1799 (16.69)
 2 1 222 681 (20.10) 746 (17.02) 1886 (17.50)
 3 1 187 082 (19.51) 934 (21.30) 2114 (19.62)
 4 1 176 829 (19.35) 951 (21.69) 2338 (21.70)
 5 (most deprived) 1 23 1431 (20.24) 905 (20.64) 2612 (24.24)
 Not recorded 26 504 (0.44) * 27 (0.25)
Accommodation:
 Neither homeless nor care home resident 6 036 288 (99.23) 3345 (76.30) 9895 (91.82)
 Care home or nursing home resident 35 813 (0.59) 1033 (23.56) 854 (7.93)
 Homeless 11 001 (0.18) * 27 (0.25)
Body mass index:
 <18.5 161 579 (2.66) 203 (4.63) 260 (2.41)
 18.5-24.99 2 033 809 (33.43) 1345 (30.68) 2708 (25.13)
 25-29.99 1 723 494 (28.33) 1291 (29.45) 3406 (31.61)
 30-34.99 800 857 (13.17) 738 (16.83) 2126 (19.73)
 ≥35 453 323 (7.45) 460 (10.49) 1549 (14.37)
 Not recorded 910 040 (14.96) 347 (7.92) 727 (6.75)
Smoking status:
 Non-smoker 3 482 456 (57.25) 2312 (52.74) 6073 (56.36)
 Ex-smoker 1 291 953 (21.24) 1735 (39.58) 3716 (34.48)
 Light smoker 803 783 (13.21) 199 (4.54) 668 (6.20)
 Moderate smoker 153 680 (2.53) 32 (0.73) 97 (0.90)
 Heavy smoker 70 215 (1.15) 18 (0.41) 62 (0.58)
 Not recorded 281 015 (4.62) 88 (2.01) 160 (1.48)
Chronic kidney disease (CKD):
 No CKD 5 843 919 (96.07) 2928 (66.79) 8156 (75.69)
 CKD3 2 14193 (3.52) 1190 (27.14) 2010 (18.65)
 CKD4 12 654 (0.21) 141 (3.22) 252 (2.34)
 CKD5 only 7286 (0.12) 96 (2.19) 239 (2.22)
 CKD5 with dialysis 1676 (0.03) 14 (0.32) 46 (0.43)
 CKD5 with transplant 3374 (0.06) 15 (0.34) 73 (0.68)
table 2 | Demographic and medical characteristics of derivation cohort and cohort members with outcomes. values are numbers (percentages) unless 
stated otherwise
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on QResearch have been validated internationally and 
found to have good performance outside of the UK.29 30
comparison with other studies
Although similarities exist between our study and the 
recently reported analysis of risk factors from another 
English general practice database using a different 
clinical computer system, our project had a different 
aim—namely, to develop and evaluate a risk prediction 
model. We used a more comprehensive outcome 
(including deaths in patients with positive tests for 
SARS-CoV-2), a much wider range of predictors, and 
a more granular assessment of ethnicity and body 
mass index. Our C statistic for mortality (>0.92) is 
substantially higher than the previous study’s reported 
value of 0.77.31 Other prediction models have been 
reported, although these focus on other outcomes of 
covid-19, including risk of admission to intensive care or 
death following a positive test, or clinical decision tools 
that integrate biochemical and imaging parameters to 
aid diagnostis.13 However, most such studies are at 
high risk of bias, as they have been developed in highly 
selected cohorts, have limited transparency, are likely 
to have optimistic reported performance, or did not 
use covid-19 specific data.13 This study represents a 
substantial improvement on previously developed risk 
algorithms in terms of the size and representativeness 
of the study population, the richness of data linkages 
enabling accurate ascertainment of cases (including 
both in-hospital and out of hospital deaths) across the 
health network, and the breadth of candidate predictor 
variables considered. Importantly, it analyses risks 
at the population level, rather than risks in people 
with confirmed or suspected infection, and may have 
relevance for shielding or other policies that seek to 
mitigate risk of viral exposure.
table 2 | continued
characteristic
Derivation cohort—total 
(n=6 083 102)
Derivation cohort—covid-19 
deaths (n=4384)
Derivation cohort—covid-19 
admission (n=10 776)
Learning disability:
 No learning disability 5 972 982 (98.19) 4110 (93.75) 10251 (95.13)
 Learning disability 107107 (1.76) 255 (5.82) 498 (4.62)
 Down’s syndrome 3013 (0.05) 19 (0.43) 27 (0.25)
Chemotherapy:
 No chemotherapy in previous 12 months 6 059 236 (99.61) 4267 (97.33) 10482 (97.27)
 Chemotherapy group A 9307 (0.15) 33 (0.75) 71 (0.66)
 Chemotherapy group B 13 600 (0.22) 75 (1.71) 200 (1.86)
 Chemotherapy group C 959 (0.02) * 23 (0.21)
Cancer and immunosuppression:
 Blood cancer 28 089 (0.46) 114 (2.60) 238 (2.21)
 Bone marrow or stem cell transplant in previous 6 months 194 (0.00) * *
 Respiratory cancer 12 792 (0.21) 61 (1.39) 130 (1.21)
 Radiotherapy in previous 6 months 12 129 (0.20) 56 (1.28) 125 (1.16)
 Solid organ transplant 3209 (0.05) 10 (0.23) 33 (0.31)
 GP prescribed immunosuppressant medication 7990 (0.13) 19 (0.43) 53 (0.49)
 Prescribed leukotriene or LABA 13 0895 (2.15) 399 (9.10) 874 (8.11)
 Prescribed regular prednisolone 32 929 (0.54) 176 (4.01) 388 (3.60)
 Sickle cell disease 2125 (0.03) * 28 (0.26)
Other comorbidities:
 Type 1 diabetes 28 587 (0.47) 36 (0.82) 136 (1.26)
 Type 2 diabetes 394 562 (6.49) 1417 (32.32) 3017 (28.00)
 Chronic obstructive pulmonary disease 142 107 (2.34) 580 (13.23) 1155 (10.72)
 Asthma 825 422 (13.57) 584 (13.32) 1745 (16.19)
 Rare pulmonary diseases 33 433 (0.55) 96 (2.19) 240 (2.23)
 Pulmonary hypertension or pulmonary fibrosis 4940 (0.08) 40 (0.91) 83 (0.77)
 Coronary heart disease 215 069 (3.54) 1038 (23.68) 1779 (16.51)
 Stroke 129 699 (2.13) 809 (18.45) 1339 (12.43)
 Atrial fibrillation 147 528 (2.43) 832 (18.98) 1461 (13.56)
 Congestive cardiac failure 70 970 (1.17) 575 (13.12) 1005 (9.33)
 Venous thromboembolism 105 136 (1.73) 381 (8.69) 753 (6.99)
 Peripheral vascular disease 44 476 (0.73) 289 (6.59) 467 (4.33)
 Congenital heart disease 31 576 (0.52) 48 (1.09) 100 (0.93)
 Dementia 58 873 (0.97) 1311 (29.90) 1235 (11.46)
 Parkinson’s disease 15 315 (0.25) 137 (3.13) 218 (2.02)
 Epilepsy 80 064 (1.32) 159 (3.63) 348 (3.23)
 Rare neurological conditions 18 603 (0.31) 42 (0.96) 120 (1.11)
 Cerebral palsy 6481 (0.11) * 27 (0.25)
 Severe mental illness 672 494 (11.06) 745 (16.99) 1841 (17.08)
 Osteoporotic fracture 238 276 (3.92) 675 (15.40) 1154 (10.71)
 Rheumatoid arthritis or SLE 60 847 (1.00) 127 (2.90) 309 (2.87)
 Cirrhosis of liver 11 865 (0.20) 37 (0.84) 106 (0.98)
GP=general practitioner; LABA=long acting β agonist; SLE=systemic lupus erythematosus.
*Value suppressed owing to small numbers (<15).
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Townsend material deprivation score (5 unit increase)
White
Indian
Pakistani
Bangladeshi
Other Asian
Caribbean
Black African
Chinese
Other ethnic group
Not in care home or homeless
Lives in residential or nursing home
Homeless according to GP records
No learning disability
Learning disability apart from Down's syndrome
Down's syndrome
No kidney failure
Chronic kidney disease stage 3
Chronic kidney disease stage 4
Chronic kidney disease stage 5
Chronic kidney disease stage 5 with dialysis
Chronic kidney disease statge 5 with transplant
Not on chemotherapy in past 12 months
Chemotherapy grade A
Chemotherapy grade B
Chemotherapy grade C
Blood cancer
Bone marrow or stem cell transplant in past 6 months
Respiratory tract cancer
Radiotherapy in past 6 months
Solid organ transplant (excluding kidney and bone marrow)
Immunosuppressant medication from  GP 4+ scripts in past 6 months
Leukotriene or long acting β agonist 4+ scripts in past 6 months
Oral steroids 4+ scripts in past 6 months
Sickle cell disease or severe immunodeficiency
Type 1 diabetes
Type 2 diabetes
Chronic obstructive pulmonary disease
Pulmonary hypertension or pulmonary fibrosis
Rare lung conditions (bronchiectasis, cystic fibrosis, or alveolitis)
Asthma
Coronary heart disease
Stroke
Atrial fibrillation
Congestive cardiac failure
Thrombo-embolism
Peripheral vascular disease
Congenital heart disease
Dementia
Parkinson's disease
Epilepsy
Motor neurone disease, multiple sclerosis, myaesthenia gravis,  or Huntington's
Cerebral palsy
Severe mental illness
Osteoporotic fracture (hip, spine, wrist, humerus)
Rheumatoid arthritis or SLE
Cirrhosis of liver
1.48 (1.37 to 1.61)
1.00 (1.00 to 1.00)
1.89 (1.43 to 2.51)
1.40 (0.91 to 2.14)
1.41 (0.88 to 2.26)
1.19 (0.72 to 1.97)
1.68 (1.29 to 2.20)
1.98 (1.39 to 2.83)
1.21 (0.51 to 2.90)
1.73 (1.28 to 2.35)
1.00 (1.00 to 1.00)
3.61 (3.18 to 4.10)
1.48 (0.21 to 10.52)
1.00 (1.00 to 1.00)
1.36 (1.11 to 1.65)
32.55 (18.13 to 58.42)
1.00 (1.00 to 1.00)
1.30 (1.17 to 1.45)
1.37 (1.05 to 1.80)
3.00 (2.19 to 4.12)
2.68 (0.86 to 8.36)
7.84 (3.38 to 18.17)
1.00 (1.00 to 1.00)
2.30 (1.35 to 3.94)
3.52 (2.29 to 5.42)
17.31 (6.52 to 45.98)
1.50 (1.06 to 2.12)
2.78 (0.22 to 34.55)
1.70 (1.16 to 2.49)
2.11 (1.30 to 3.41)
1.46 (0.36 to 5.92)
1.09 (0.56 to 2.10)
1.23 (0.78 to 1.94)
1.83 (1.52 to 2.19)
5.94 (1.89 to 18.67)
4.02 (2.07 to 7.82)
6.29 (4.08 to 9.70)
1.50 (1.29 to 1.74)
0.84 (0.73 to 0.97)
0.85 (0.60 to 1.19)
1.55 (1.00 to 2.40)
1.24 (1.10 to 1.40)
1.34 (1.19 to 1.51)
1.18 (1.04 to 1.34)
1.37 (1.18 to 1.60)
1.18 (1.01 to 1.38)
1.42 (1.15 to 1.76)
1.23 (0.75 to 2.03)
2.91 (2.58 to 3.28)
1.13 (0.79 to 1.62)
1.58 (1.23 to 2.03)
2.75 (1.83 to 4.12)
3.45 (1.10 to 10.78)
1.29 (1.15 to 1.45)
1.12 (1.00 to 1.26)
1.32 (1.06 to 1.65)
1.85 (1.15 to 2.99)
0.015 1 64
Adjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)
No diabetes 1.00 (1.00 to 1.00)
Fig 1 | adjusted hazard ratio (95% ci) of death from covid-19 in women in derivation cohort, adjusted for variables shown, deprivation, and 
fractional polynomial terms for body mass index (bMi) and age. Model includes fractional polynomial terms for age (3 3) and bMi (0.5 0.5 ln(bmi)) 
and interaction terms between age terms and type 2 diabetes. Hazard ratio for type 2 diabetes reported at mean age. gp=general practitioner; 
sle=systemic lupus erythematosus. (Qresearch database version 44; study period 24 january 2020 to 30 april 2020)
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Atrial fibrillation
Pulmonary hypertension or pulmonary fibrosis
Rare lung conditions (bronchiectasis, cystic fibrosis, or alveolitis)
Townsend material deprivation score (5 unit increase)
White
Indian
Pakistani
Bangladeshi
Other Asian
Caribbean
Black African
Chinese
Other ethnic group
Not in care home or homeless
Lives in residential or nursing home
Homeless according to GP records
No learning disability
Learning disability apart from Down's syndrome
Down's syndrome
No kidney failure
Chronic kidney disease stage 3
Chronic kidney disease stage 4
Chronic kidney disease stage 5
Chronic kidney disease stage 5 with dialysis
Chronic kidney disease statge 5 with transplant
Not on chemotherapy in past 12 months
Chemotherapy grade A
Chemotherapy grade B
Chemotherapy grade C
Blood cancer
Bone marrow or stem cell transplant in last 6 months
Respiratory tract cancer
Radiotherapy in past 6 months
Solid organ transplant (excluding kidney and bone marrow)
Immunosuppressant medication from  GP 4+ scripts in past 6 months
Leukotriene or long acting β agonist 4+ scripts in past 6 months
Oral steroids 4+ scripts in past 6 months
Type 1 diabetes
Type 2 diabetes
Chronic obstructive pulmonary disease
Asthma
Coronary heart disease
Stroke
Congestive cardiac failure
Thrombo-embolism
Peripheral vascular disease
Congenital heart disease
Dementia
Parkinson's disease
Epilepsy
Motor neurone disease, multiple sclerosis, myaesthenia gravis, or Huntington's
Cerebral palsy
Severe mental illness
Osteoporotic fracture (hip, spine, wrist, humerus)
Rheumatoid arthritis or SLE
Cirrhosis of liver
1.50 (1.40 to 1.61)
1.00 (1.00 to 1.00)
1.59 (1.25 to 2.01)
1.84 (1.39 to 2.44)
2.27 (1.65 to 3.12)
2.02 (1.49 to 2.74)
2.06 (1.65 to 2.57)
3.03 (2.42 to 3.80)
2.47 (1.49 to 4.09)
2.04 (1.60 to 2.58)
1.00 (1.00 to 1.00)
4.28 (3.80 to 4.83)
1.56 (0.65 to 3.76)
1.00 (1.00 to 1.00)
1.36 (1.14 to 1.60)
9.80 (4.62 to 20.78)
1.00 (1.00 to 1.00)
1.18 (1.06 to 1.30)
1.83 (1.46 to 2.29)
2.40 (1.83 to 3.15)
3.67 (2.02 to 6.66)
3.20 (1.62 to 6.33)
1.00 (1.00 to 1.00)
1.74 (1.10 to 2.75)
3.50 (2.54 to 4.82)
3.37 (1.17 to 9.64)
1.29 (0.97 to 1.71)
6.10 (1.11 to 33.54)
1.27 (0.89 to 1.81)
2.09 (1.48 to 2.96)
1.72 (0.71 to 4.21)
1.58 (0.95 to 2.62)
1.04 (0.64 to 1.70)
1.44 (1.19 to 1.73)
4.41 (1.41 to 13.81)
5.84 (3.97 to 8.60)
4.74 (3.34 to 6.71)
1.25 (1.11 to 1.42)
1.03 (0.91 to 1.17)
1.20 (0.93 to 1.56)
1.47 (0.93 to 2.32)
1.13 (1.02 to 1.24)
1.24 (1.11 to 1.38)
1.11 (1.00 to 1.24)
1.40 (1.24 to 1.59)
1.36 (1.18 to 1.57)
1.38 (1.19 to 1.61)
1.03 (0.72 to 1.47)
3.14 (2.81 to 3.50)
1.93 (1.59 to 2.35)
1.60 (1.30 to 1.97)
1.99 (1.24 to 3.18)
2.77 (1.23 to 6.23)
1.26 (1.13 to 1.42)
1.41 (1.24 to 1.61)
1.02 (0.75 to 1.38)
1.29 (0.83 to 2.02)
0.031 1 32
Adjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)
Sickle cell disease or severe immunodeficiency
No diabetes 1.00 (1.00 to 1.00)
Fig 2 | adjusted hazard ratio (95% ci) of death from covid-19 in men in derivation cohort, adjusted for variables shown, deprivation, and fractional 
polynomial terms for body mass index (bMi) and age. Model includes fractional polynomial terms for age (1 3) and bMi (−0.5 −0.5 ln(age)) and 
interaction terms between age terms and type 2 diabetes. Hazard ratio for type 2 diabetes reported at mean age. gp=general practitioner; 
sle=systemic lupus erythematosus. (Qresearch database version 44; study period 24 january 2020 to 30 april 2020)
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Townsend material deprivation score (5 unit increase)
White
Indian
Pakistani
Bangladeshi
Other Asian
Caribbean
Black African
Chinese
Other ethnic group
Not in care home or homeless
Lives in residential or nursing home
Homeless according to GP records
No learning disability
Learning disability apart from Down's syndrome
Down's syndrome
No kidney failure
Chronic kidney disease stage 3
Chronic kidney disease stage 4
Chronic kidney disease stage 5
Chronic kidney disease stage 5 with dialysis
Chronic kidney disease statge 5 with transplant
Not on chemotherapy in last 12 months
Chemotherapy grade A
Chemotherapy grade B
Chemotherapy grade C
Blood cancer
Bone marrow or stem cell transplant in past 6 months
Respiratory tract cancer
Radiotherapy in past 6 months
Solid organ transplant (excluding kidney and bone marrow)
Immunosuppressant medication from  GP 4+ scripts in past 6 months
Leukotriene or long acting β agonist 4+ scripts in past 6 months
Oral steroids 4+ scripts in past 6 months
Type 1 diabetes
Type 2 diabetes
Chronic obstructive pulmonary disease
Asthma
Coronary heart disease
Stroke
Congestive cardiac failure
Thrombo-embolism
Peripheral vascular disease
Congenital heart disease
Dementia
Parkinson's disease
Epilepsy
Motor neurone disease, multiple sclerosis, myaesthenia gravis or Huntington's
Cerebral palsy
Severe mental illness
Osteoporotic fracture (hip, spine, wrist, humerus)
Rheumatoid arthritis or SLE
Cirrhosis of the liver
1.52 (1.45 to 1.60)
1.00 (1.00 to 1.00)
1.89 (1.60 to 2.24)
1.52 (1.21 to 1.89)
1.41 (1.11 to 1.79)
2.14 (1.74 to 2.64)
2.01 (1.71 to 2.35)
2.30 (1.97 to 2.68)
1.15 (0.71 to 1.85)
1.90 (1.64 to 2.21)
1.00 (1.00 to 1.00)
1.84 (1.64 to 2.07)
1.23 (0.55 to 2.74)
1.00 (1.00 to 1.00)
1.53 (1.34 to 1.76)
8.84 (5.37 to 14.55)
1.00 (1.00 to 1.00)
1.35 (1.25 to 1.46)
1.79 (1.48 to 2.17)
4.17 (3.39 to 5.12)
3.72 (2.06 to 6.75)
5.54 (3.55 to 8.67)
1.00 (1.00 to 1.00)
2.11 (1.48 to 3.01)
4.19 (3.28 to 5.37)
15.53 (8.36 to 28.85)
1.40 (1.10 to 1.78)
1.21 (0.24 to 5.97)
1.65 (1.25 to 2.17)
1.47 (1.07 to 2.04)
1.57 (0.80 to 3.05)
1.32 (0.94 to 1.84)
1.31 (1.04 to 1.64)
1.92 (1.71 to 2.17)
6.68 (4.06 to 10.97)
4.03 (3.12 to 5.22)
2.64 (2.27 to 3.07)
1.34 (1.21 to 1.49)
1.12 (1.04 to 1.21)
1.28 (1.06 to 1.55)
1.60 (1.19 to 2.14)
1.11 (1.02 to 1.22)
1.39 (1.27 to 1.53)
1.34 (1.22 to 1.47)
1.38 (1.23 to 1.55)
1.34 (1.21 to 1.50)
1.21 (1.03 to 1.44)
1.20 (0.88 to 1.65)
1.73 (1.56 to 1.92)
1.70 (1.32 to 2.18)
1.57 (1.33 to 1.86)
2.47 (1.90 to 3.22)
2.66 (1.42 to 4.98)
1.37 (1.28 to 1.47)
1.35 (1.24 to 1.47)
1.35 (1.17 to 1.56)
1.83 (1.35 to 2.49)
0.031 1 32
Adjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)
Pulmonary hypertension or pulmonary fibrosis
Rare lung conditions (bronchiectasis, cystic fibrosis, or alveolitis)
Sickle cell disease or severe immunodeficiency
Atrial fibrillation
No diabetes 1.00 (1.00 to 1.00)
Fig 3 | adjusted hazard ratio (95%ci) of hospital admission for covid-19 in women in derivation cohort, adjusted for variables shown, deprivation, 
fractional polynomial terms for body mass index (bMi) and age. Model includes fractional polynomial terms for age (0.5, 2) and bMi (−2 0) and 
interaction terms between age terms and type 2 diabetes. Hazard ratio for type 2 diabetes reported at mean age. gp=general practitioner; 
sle=systemic lupus erythematosus. (Qresearch database version 44; study period 24 january 2020 to 30 april 2020)
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Sickle cell disease or severe immunodeficiency
Pulmonary hypertension or pulmonary fibrosis
Rare lung conditions (bronchiectasis, cystic fibrosis, or alveolitis)
Townsend material deprivation score (5 unit increase)
White
Indian
Pakistani
Bangladeshi
Other Asian
Caribbean
Black African
Chinese
Other ethnic group
Not in carehome or homeless
Lives in residential or nursing home
Homeless according to GP records
No learning disability
Learning disability apart from Down's Syndrome
Down's syndrome
No kidney failure
Chronic kidney disease stage 3
Chronic kidney disease stage 4
Chronic kidney disease stage 5
Chronic kidney disease stage 5 with dialysis
Chronic kidney disease statge 5 with transplant
Not on chemotherapy in past 12 months
Chemotherapy grade A
Chemotherapy grade B
Chemotherapy grade C
Blood cancer
Bone marrow or stem cell transplant in past 6 months
Respiratory tract cancer
Radiotherapy in past 6 months
Solid organ transplant (excluding kidney and bone marrow)
Immunosuppressant medication from  GP 4+ scripts in past 6 months
Leukotriene or long acting β agonist 4+ scripts in past 6 months
Oral steroids 4+ scripts in past 6 months
Type 1 diabetes
Type 2 diabetes (see note)
Chronic obstructive pulmonary disease
Asthma
Coronary heart disease
Stroke
Congestive cardiac failure
Thrombo-embolism
Peripheral vascular disease
Congenital heart disease
Dementia
Parkinson's disease
Epilepsy
Motor neurone disease, multiple sclerosis, myaesthenia gravis or Huntington's
Cerebral palsy
Severe mental illness
Osteoporotic fracture (hip, spine, wrist, humerus)
Rheumatoid arthritis or SLE
Cirrhosis of the liver
1.46 (1.40 to 1.53)
1.00 (1.00 to 1.00)
2.15 (1.89 to 2.44)
2.01 (1.72 to 2.36)
1.71 (1.41 to 2.08)
2.29 (1.91 to 2.74)
2.29 (1.99 to 2.63)
2.59 (2.27 to 2.97)
1.51 (1.03 to 2.20)
2.12 (1.83 to 2.46)
1.00 (1.00 to 1.00)
2.52 (2.25 to 2.82)
1.50 (0.97 to 2.30)
1.00 (1.00 to 1.00)
1.38 (1.22 to 1.56)
4.36 (2.39 to 7.94)
1.00 (1.00 to 1.00)
1.28 (1.19 to 1.38)
2.00 (1.67 to 2.39)
3.86 (3.25 to 4.58)
5.90 (4.22 to 8.25)
7.09 (5.30 to 9.47)
1.00 (1.00 to 1.00)
1.72 (1.24 to 2.37)
3.64 (2.95 to 4.49)
4.11 (2.20 to 7.68)
1.29 (1.05 to 1.57)
1.70 (0.49 to 5.94)
1.44 (1.14 to 1.83)
2.02 (1.59 to 2.55)
2.02 (1.27 to 3.21)
1.12 (0.81 to 1.54)
1.18 (0.89 to 1.58)
1.42 (1.25 to 1.62)
4.87 (2.67 to 8.87)
3.66 (2.90 to 4.62)
2.57 (2.27 to 2.91)
1.36 (1.25 to 1.49)
1.10 (1.02 to 1.19)
1.29 (1.07 to 1.54)
1.56 (1.12 to 2.17)
1.06 (0.99 to 1.14)
1.31 (1.20 to 1.42)
1.19 (1.10 to 1.29)
1.33 (1.21 to 1.46)
1.30 (1.17 to 1.44)
1.27 (1.13 to 1.42)
0.97 (0.75 to 1.25)
2.12 (1.92 to 2.34)
2.05 (1.74 to 2.41)
1.75 (1.52 to 2.02)
3.34 (2.60 to 4.29)
2.85 (1.76 to 4.62)
1.28 (1.19 to 1.38)
1.35 (1.22 to 1.50)
1.30 (1.07 to 1.57)
1.88 (1.46 to 2.41)
81521.0
Adjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95% CI)
No diabetes 1.00 (1.00 to 1.00)
Fig 4 | adjusted hazard ratio (95% ci) of hospital admission for covid-19 in men in derivation cohort, adjusted for variables shown, deprivation, 
and fractional polynomial terms for body mass index (bMi) and age. Model includes fractional polynomial terms for age (−2 2) and bMi (−0.5 0) 
and interaction terms between age terms and type 2 diabetes. Hazard ratio for type 2 diabetes reported at mean age. gp=general practitioner; 
sle=systemic lupus erythematosus. (Qresearch database version 44; study period 24 january 2020 to 30 april 2020)
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complexities of modelling 
Several complexities of modelling adverse risks from 
covid-19 in the general population warrant discussion. 
We used a general population approach which, 
although not able to incorporate all determinants of 
being infected, offers an overall estimate of risk of 
adverse outcomes from covid-19 that could be used 
in discussions between clinicians and patients about 
adjustment of lifestyle or occupational and behavioural 
factors that could limit viral exposure. Our model 
predicts risks of “catching covid-19 and then having a 
severe outcome,” on the basis of data collected during 
the first peak of the pandemic. The endpoint in this 
study examines a risk trajectory that comprises two 
elements: becoming infected, which is predominantly 
a function of behavioural/environmental factors 
including occupation, local infection rate, and numbers 
of social interactions; and risk of hospital admission 
and death due to the infection, which is arguably 
primarily driven by “vulnerability” (that is, biological/
physiological factors including age, sex, body mass 
index, comorbidities, and medications). Although 
producing a prediction model for risk of “death if 
infected” is feasible in principle, this approach is not 
yet possible owing to the approach to testing in the UK 
and the context of an as yet incompletely quantified 
degree of asymptomatic background transmission. 
Limited covid-19 testing data are available, but the 
difficulty is that no systematic community testing was 
done in the UK during the study period, so only patients 
unwell enough to attend hospital were tested. This 
means that a risk score developed in those who tested 
positive would overestimate risks of severe outcomes. 
As more widespread testing is done and those data 
become available, we will be able to update the model 
to take background infection rates into account and 
also model regional differences. Although the absolute 
risk levels will of course change over time, depending 
on the incidence of the disease, our analysis over two 
validation time periods indicates that the relative 
risk measures and discrimination are likely to remain 
stable.
Secondly, the model estimates the absolute risk for 
a non-infected individual in the general population 
of becoming infected and then dying (or needing to 
be admitted to hospital) from the virus over a 97 day 
period. Although many more than 40 000 people 
have died from covid-19 in the UK to date, when the 
denominator is a population of multi-millions, the 
absolute risk for most people may be low. Therefore, 
when conveying this type of risk score to an individual, 
due emphasis is needed on the different meanings of 
absolute and relative risk.
Thirdly, the absolute risk of catching covid-19 
depends not only on the incidence of the infection but 
also on the number of people one gets close to. For this 
reason, non-pharmacological interventions such as 
social distancing and shielding were introduced in the 
UK during the study period. We have included some 
measures of multi-occupancy, as we have factored care 
homes into the analysis. The data generated during the 
study period will therefore be affected by the uptake of 
table 3 | performance of risk models to predict risk of death and hospital admission due to covid-19 in validation cohort 
in first validation period (24 january to 30 april 2020) and second temporal validation (1 May to 30 june 2020). values 
are estimates (95% cis) unless stated otherwise
covid-19 death covid-19 admission
Women Men Women Men
period 1
R2 statistic (%) 74.0 (72.7 to 75.3) 73.1 (71.9 to 74.3) 57.1 (55.5 to 58.8) 58.1 (56.7 to 59.5)
D statistic 3.46 (3.34 to 3.57) 3.37 (3.27 to 3.47) 2.36 (2.28 to 2.44) 2.41 (2.34 to 2.48)
Harrell’s C 0.933 (0.923 to 0.944) 0.928 (0.919 to 0.938) 0.847 (0.836 to 0.857) 0.860 (0.852 to 0.868)
Brier score 0.0007 0.0009 0.0015 0.0019
period 2
R2 statistic (%) 75.4 (73.5 to 77.4) 73.6 (71.6 to 75.6) 45.4 (41.7 to 49.1) 55.4 (52.2 to 58.5)
D statistic 3.59 (3.4 to 3.77) 3.42 (3.24 to 3.59) 1.87 (1.73 to 2) 2.28 (2.14 to 2.42)
Harrell’s C 0.952 (0.938 to 0.965) 0.933 (0.918 to 0.949) 0.776 (0.753 to 0.800) 0.833 (0.812 to 0.853)
Brier score 0.0002 0.0003 0.0004 0.0004
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Fig 5 | Funnel plots of discrimination using Harrell’s c statistic for each general practice 
in validation cohort versus number of deaths in each practice in men (top panel) and 
women (bottom panel) in first validation period
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Fig 6 | predicted and observed risk of covid-19 related hospital admission and death in validation cohort in first study period (24 january to 30 april 
2020) and in second study period (1 May to 30 june 2020), and recalibrated predicted and observed risk of covid-19 related death in validation 
cohort in second study period (1 May to 30 june 2020)
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interventions such as social distancing and shielding, 
intended to mitigate the risks of SARS-CoV-2 infection. 
This could result in underestimation of some model 
coefficients and hence underestimation of absolute 
risk in people who were shielded. Also, as this is a 
prediction model derived from an observational study, 
the associations estimated for individual predictor 
variables should not be interpreted as causal effects.
However, ethical questions must be considered 
regarding how the tools may be used. We have presented 
two ways of stratifying risk based on either absolute or 
relative risk measures with associated centile values, 
but the choice of whether to have a threshold (given 
that risk is a continuous measure), and if so what 
threshold, will depend on the purpose for which 
the risk assessment tool is to be used, the available 
resources, and the ethical framework for decision 
making. We have analysed this within the “four ethical 
principles” framework that is widely used in medical 
decision making. The four principles are autonomy, 
beneficence, justice, and non-maleficence.32 The new 
risk equations, when implemented in clinical software, 
are designed to provide more accurate information for 
patients and clinicians on which to base decisions, 
thereby promoting shared decision making and patient 
autonomy. They are intended to result in clinical 
benefit by identifying where changes in management 
are likely to benefit patients, thereby promoting the 
principle of beneficence. Justice can be achieved by 
ensuring that the use of the risk equations results 
in fair and equitable access to health services that is 
commensurate with patients’ level of risk. Lastly, the 
risk assessment must not be used in a way that causes 
harm either to the individual patient or to others (for 
example, by introducing or withdrawing treatments 
where this is not in the patient’s best interest), thereby 
supporting the non-maleficence principle. How this 
applies in clinical practice will naturally depend on 
many factors, especially the patient’s wishes, the 
evidence base for any interventions, the clinician’s 
experience, national priorities, and the available 
resources. The risk assessment equations therefore 
supplement clinical decision making and do not 
replace it. With these caveats, the predicted risk 
estimates can be used to identify people at higher risk, 
to inform shared decision making between healthcare 
professionals and service users, or for population level 
stratification.
strengths and limitations of study
Our study has some major strengths, but some 
important limitations, which include the specific 
factors related to covid-19 along with others that 
are similar to those for a range of other widely used 
clinical risk prediction algorithms developed using 
the QResearch database.14-16 Key strengths include the 
use of a very large validated data source that has been 
used to develop other risk prediction tools; the wealth 
of candidate risk predictors; the prospective recording 
of outcomes and their ascertainment using multiple 
national level database linkage; lack of selection, 
recall and respondent biases; and robust statistical 
analysis. We have used non-linear terms for body mass 
index and age. We examined interaction terms, which 
table 4 | sensitivity for covid-19 related death over 97 days in validation cohort (24 january to 30 april 2020) 
comprising 2 173 056 patients with 1722 covid-19 related deaths at different absolute risk thresholds*
top centile
total patients in each 
centile
absolute risk centile cut-
off (%)
total deaths in each absolute 
risk centile
cumulative % deaths based  
on absolute risk (sensitivity†)
1 21730 0.9093 708 41.11
2 21731 0.5182 263 56.39
3 21730 0.3703 136 64.29
4 21731 0.2892 105 70.38
5 21730 0.2369 92 75.73
6 21731 0.1990 58 79.09
7 21730 0.1702 35 81.13
8 21731 0.1473 46 83.80
9 21731 0.1288 26 85.31
10 21730 0.1135 24 86.70
11 21731 0.1004 18 87.75
12 21730 0.0895 19 88.85
13 21731 0.0800 19 89.95
14 21730 0.0719 18 91.00
15 21731 0.0647 7 91.41
16 21730 0.0584 5 91.70
17 21731 0.0528 14 92.51
18 21731 0.0477 12 93.21
19 21730 0.0432 9 93.73
20 21731 0.0393 5 94.02
21 21730 0.0357 6 94.37
22 21731 0.0325 9 94.89
23 21730 0.0296 6 95.24
24 21731 0.0270 4 95.47
25 21731 0.0246 9 95.99
*Centile value giving cut-off of predicted risk over 97 days for defining each group of absolute risk.
†Percentage of total deaths over 97 days that occurred within group of patients above predicted risk threshold.
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characteristic
total population 
(n=2 173 056)
total (column %) in top 5%  
predicted risk (n=108 652)
top 5% predicted risk 
(row %)
Male sex 1 075 788 63 755 (58.68) 5.93
Age band:
 19-29 years 424 125 * *
 30-39 years 417 590 * *
 40-49 years 358 695 97 (0.09) 0.03
 50-59 years 358 820 1028 (0.95) 0.29
 60-69 years 270 340 6428 (5.92) 2.38
 70-79 years 209 557 25 542 (23.51) 12.19
 ≥80 years 133 929 75 547 (69.53) 56.41
Ethnicity:
 White 1 780 507 90 958 (83.71) 5.11
 Indian 64 184 3034 (2.79) 4.73
 Pakistani 40 718 1863 (1.71) 4.58
 Bangladeshi 28 050 1247 (1.15) 4.45
 Other Asian 42 607 1489 (1.37) 3.49
 Caribbean 28 741 3702 (3.41) 12.88
 Black African 58 115 2884 (2.65) 4.96
 Chinese 29 972 603 (0.55) 2.01
 Other ethnic group 100 162 2872 (2.64) 2.87
Townsend deprivation fifth:
 1 (most affluent) 446 359 20 010 (18.42) 4.48
 2 428 735 20 524 (18.89) 4.79
 3 439 846 23 758 (21.87) 5.40
 4 436 574 23 644 (21.76) 5.42
 5 (most deprived) 409 917 20 437 (18.81) 4.99
 Townsend not recorded 11 625 279 (0.26) 2.40
Accommodation:
 Neither homeless or care home resident 2 155 199 97 210 (89.47) 4.51
 Care home or nursing home resident 14 057 11 269 (10.37) 80.17
 Homeless 3800 173 (0.16) 4.55
Body mass index:
 <18.5 59 376 4188 (3.85) 7.05
 18.5-24.99 711 186 33 122 (30.48) 4.66
 25-29.99 596 942 34 044 (31.33) 5.70
 30-34.99 278 830 18 762 (17.27) 6.73
 ≥35 160 345 13 086 (12.04) 8.16
 Not recorded 366 377 5450 (5.02) 1.49
Chronic kidney disease (CKD)
 No CKD 2 087 614 68 710 (63.24) 3.29
 CKD3 76 600 34 418 (31.68) 44.93
 CKD4 4648 3194 (2.94) 68.72
 CKD5 only 2527 1722 (1.58) 68.14
 CKD5 with dialysis 585 274 (0.25) 46.84
 CKD5 with transplant 1082 334 (0.31) 30.87
Learning disability:
 No learning disability 2 137 759 103 919 (95.64) 4.86
 Learning disability 34 257 4473 (4.12) 13.06
 Down’s syndrome 1040 260 (0.24) 25.00
Chemotherapy:
 No chemotherapy in previous 12 months 2 164 341 105 131 (96.76) 4.86
 Chemotherapy group A 3343 1100 (1.01) 32.90
 Chemotherapy group B 5032 2223 (2.05) 44.18
 Chemotherapy group C 340 198 (0.18) 58.24
Cancer and immunosuppression:
 Blood cancer 10 359 3084 (2.84) 29.77
 Bone marrow or stem cell transplant in previous 6 months 73 56 (0.05) 76.71
 Respiratory cancer 4549 1722 (1.58) 37.85
 Radiotherapy in previous 6 months 4346 1709 (1.57) 39.32
 Solid organ transplant 1147 283 (0.26) 24.67
 GP prescribed immunosuppressant medication 2814 455 (0.42) 16.17
 Prescribed leukotriene or LABA 45 905 9591 (8.83) 20.89
 Prescribed regular prednisolone 11 617 4518 (4.16) 38.89
 Sickle cell disease 717 117 (0.11) 16.32
table 5 | summary characteristics for top 5% of patients with highest predicted absolute risks of covid-19 death. table 
shows results for all members of validation cohort
(Continued)
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show increased risks at younger ages for adults with 
type 2 diabetes. We also established a new linkage 
to the systemic anti-cancer therapy (SACT) database 
for chemotherapy prescribed and administered in 
secondary care (which may not be recorded well in 
general practice software) to circumvent possible 
missing data for this important variable.
Specific limitations include the occurrence of 
shielding during the study period and that the study was 
conducted during the first phase of the UK epidemic. 
We have accounted for many risk factors for covid-19 
mortality, but risks may be conferred by some rare 
medical conditions or other factors such as occupation 
that have not yet been observed or are poorly recorded 
in general practice or hospital data. In particular, the 
model does not include two important predictors—
namely, prevailing infection rate and personal social 
distancing measures. A lack of comprehensive testing 
has led to some missing data on covid-19 admissions 
and/or deaths, which means that development of a 
valid model for predicting death in people infected 
with SARS-CoV-2 is not yet possible. We acknowledge 
that absolute risks are changing during the course of 
the pandemic, so these should be interpreted with 
caution. However, we would expect predictors of risk, 
relative risk measures, and discrimination to be more 
stable over time, which is consistent with the results 
from our temporal validation. Although this tool was 
modelled on the best available data from the first 
wave of the pandemic, it will be updated as further 
testing and outcome data accrue, immunity levels 
change, and (potentially) a vaccine becomes available. 
Nevertheless, having a risk score available at this stage 
of the pandemic may be useful to identify people at 
high risk before a vaccine or treatment is available.
We have reported a validation in each of two time 
periods using practices from QResearch, but these 
practices were completely separate from those used 
to develop the model. We have used this approach 
previously to develop and validate other widely used 
prediction models. When these have been further 
externally validated on completely different clinical 
databases, by ourselves and others, the results have 
been very similar.33-35 Work is already under way to 
evaluate the models in external datasets across all 
four nations of the UK and to integrate the algorithms 
within NHS clinical software systems.
policy implication and conclusions
This study presents robust risk prediction models that 
could be used to stratify risk in populations for public 
health purposes in the event of a “second wave” of the 
pandemic and support shared management of risk. We 
anticipate that the algorithms will be updated regularly 
as understanding of covid-19 increases, as more data 
become available, as behaviour in the population 
changes, or in response to new policy interventions. 
It is important for patients/carers and clinicians that 
a common, appropriately developed, evidence based 
model exists that is consistently implemented and 
is supported by the academic, clinical, and patient 
communities. This will then help to ensure consistent 
policy and clear national communication between 
policy makers, professionals, employers, and the 
public.
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table 5 | continued
characteristic
total population 
(n=2 173 056)
total (column %) in top 5%  
predicted risk (n=108 652)
top 5% predicted risk 
(row %)
Other comorbidities:
 Type 1 diabetes 10 337 861 (0.79) 8.33
 Type 2 diabetes 137 092 40 674 (37.44) 29.67
 Chronic obstructive pulmonary disease 51 026 16 708 (15.38) 32.74
 Asthma 299 632 14 860 (13.68) 4.96
 Rare pulmonary diseases 11 748 2868 (2.64) 24.41
 Pulmonary hypertension or pulmonary fibrosis 1891 1061 (0.98) 56.11
 Coronary heart disease 77 035 29 476 (27.13) 38.26
 Stroke 47 513 20 384 (18.76) 42.90
 Atrial fibrillation 52 764 23 579 (21.70) 44.69
 Congestive cardiac failure 25 255 14 897 (13.71) 58.99
 Venous thromboembolism 38 962 10114 (9.31) 25.96
 Peripheral vascular disease 16 463 8005 (7.37) 48.62
 Congenital heart disease 11 344 1288 (1.19) 11.35
 Dementia 21 984 19 829 (18.25) 90.20
 Parkinson’s disease 5736 2847 (2.62) 49.63
 Epilepsy 29 031 3503 (3.22) 12.07
 Rare neurological conditions 6804 1092 (1.01) 16.05
 Cerebral palsy 2433 233 (0.21) 9.58
 Severe mental illness 246 668 17 428 (16.04) 7.07
 Osteoporotic fracture 87 595 15 933 (14.66) 18.19
 Rheumatoid arthritis or SLE 21 391 3251 (2.99) 15.20
 Cirrhosis of liver 4442 1054 (0.97) 23.73
GP=general practitioner; LABA=long acting β agonist; SLE=systemic lupus erythematosus.
*Values suppressed owing to small numbers <15.
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